Table 2.
Characteristics of patients according to hTERT mRNA, TA, and telomere length
| n Patients (%) | hTERT mRNA Expression, n patients (%) |
P* | TA, n patients (%) |
P* | n Patients (%) | Telomere Length, n patients (%) |
P* | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | n = 100 | Positive n = 63 (63) | Negative n = 37 (37) | Positive n = 63 (63) | Negative n = 37 (37) | n = 98 | >1 n = 34 (35) | <1 n = 64 (65) | |||
| Age, y | |||||||||||
| ≤60 | 41 (41) | 19 (46) | 22 (54) | 21 (51) | 20 (49) | 41 (42) | 20 (49) | 21 (51) | |||
| >60 | 59 (59) | 44 (75) | 15 (25) | .006* | 42 (71) | 17 (29) | .06 | 57 (58) | 14 (25) | 43 (75) | .018* |
| Sex | |||||||||||
| Female | 35 (35) | 23 (66) | 12 (34) | 22 (63) | 13 (37) | 34 (35) | 13 (38) | 21 (62) | |||
| Male | 65 (65) | 40 (61.5) | 25 (38.5) | .83 | 41 (63) | 24 (37) | 1 | 64 (65) | 21 (33) | 41 (67) | .82 |
| KPS | n = 98 | n = 96 | |||||||||
| <80 | 37 (38) | 30 (81) | 7 (19) | 29 (78) | 8 (22) | 36 (38) | 8 (22) | 28 (78) | |||
| ≥80 | 61 (62) | 31 (51) | 30 (49) | .003* | 32 (52) | 29 (48) | .01* | 60 (62) | 25 (42) | 35 (58) | .08 |
| Any therapy | |||||||||||
| Yes | 75 (75) | 42 (56) | 33 (44) | 41 (57) | 29 (40) | 70 (71) | 26 (37) | 44 (63) | |||
| No | 25 (25) | 21 (84) | 4 (16) | .016* | 22 (79) | 6 (21) | .07 | 28 (29) | 8 (29) | 6 (71) | .23 |
| MGMT promoter status | n = 99 | ||||||||||
| Methylated | 67 (68) | 41 (61) | 26 (39) | 41 (61) | 26 (39) | 66 (67) | 24 (36) | 42 (64) | |||
| Unmethylated | 32 (32) | 22 (69) | 10 (31) | .51 | 22 (69) | 10 (31) | .51 | 32 (33) | 10 (31) | 22 (69) | .66 |
| IDH1 | |||||||||||
| Mutated | 6 (6) | 0 (0) | 6 (100) | 0 (0) | 6 (100) | 6 (6) | 5 (83) | 1 (17) | |||
| Wild-type | 94 (94) | 63 (67) | 31 (33) | .003* | 63 (67) | 31 (33) | .002* | 92 (94) | 29 (32) | 63 (68) | .02* |
*P-values indicating significance